10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study investigated the relative bioavailability (rate and extend of absorption) of
Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA
with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc.,
following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult
subjects administered under non-fasting conditions.